Hosted on MSN1mon
Disc raises $225.5m as it eyes approval of rare skin disorder drug
The therapy targets erythropoietic protoporphyria (EPP), a rare genetic disorder that ... Patients who opted to continue into an open-label extension study for another 24 weeks demonstrated ...
pharmaphorum4mon
Disc maps out US filing for porphyria drug bitopertin
Disc is also running a 26-subject open-label phase 2 study of bitopertin in patients with EPP and XLP, called BEACON, which was reported at last year's American Society of Haematology (ASH ...